29th Sep 2015 07:58
LONDON (Alliance News) - Verona Pharma PLC shares were trading higher on Tuesday morning after the company said its secured positive headline data from the study conducted on its RPL554 candidate for treating chronic obstructive pulmonary disease.
Verona shares were up 10% to 4.86 pence early Tuesday, one of the best performers in the AIM All-Share.
Verona said the primary objective of the study was met, with the drug formulation well tolerated by patients at all dose levels. The RPL554 drug also resulted in a pronounced improvement in lung function in the patients and the data supports a twice-daily dosing regimen of the drug.
"The data demonstrates that, as designed, the new commercially scalable, suspension formulation is well tolerated and has allowed us to extend the dose range and the duration of bronchodilation effect that can be produced in COPD patients. We will now fully analyse the data from this trial," said Verona Chief Executive Jan-Anders Karlsson.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
VRP.L